机械类型化器官用于评估药物诱导的伤害.
Murat Kaynak1,2,3, Mehmet D Aşık3,4, Elif E Inan1,2,3
1Center for Engineering in Medicine and Surgery, Massachusetts General Hospital, Boston, MA, 02114, USA.
Advanced materials (Deerfield Beach, Fla.)
|November 5, 2025
概括
一个新的离心机械测试 (CeMeT) 平台使3D有机体的快速,无标签的机械型化成为可能. 该工具准确地检测药物诱导的伤害和疾病变化,推进临床前药物安全查.
科学领域:
- 生物医学工程 生物医学工程
- 生物物理学的生物物理.
- 毒理学 毒理学 毒理学
背景情况:
- 组织机械型是疾病和药物毒性的关键指标.
- 目前的机械造型方法对于3D有机体模型是不可扩展的.
- 需要有效的工具来选药物安全性和有效性.
研究的目的:
- 引入离心机械测试 (CeMeT) 平台用于3D有机体机械造型.
- 证明CeMeT在评估机械性能和检测病理变化的能力.
- 为了验证CeMeT用于临床前药物安全性和疗效评估.
主要方法:
- 开发并使用离心机械测试 (CeMeT) 平台.
- 采用离心机械原理和高速成像技术进行无标签分析.
- 评估了水凝和心脏器官的机械性能 (刚性,弹性恢复).
主要成果:
- CeMeT准确地区分了不同水凝和有机体的机械性能.
- 该平台检测到具有高灵敏度的病态机械型变化.
- 药物治疗 (перголид,cytochalasin-D) 诱导了有机体机械型的可测量变化,表明了毒性.
结论:
- CeMeT平台提供了一个快速,强大的,无标签的方法,用于3D有机体机械造型.
- 器官机械型变化作为药物诱导组织损伤的可靠指标.
- 在早期药物安全性评估和疾病研究方面,CeMeT具有变革性的潜力.
相关概念视频
Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Drug Toxicity: Overview
Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
Toxicity Testing in Animals
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...


